Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).

John F R RobertsonRobert E ColemanKwok Leung CheungAbigail EvansChris HolcombeAnthony SkeneDaniel ReaSamreen AhmedAli JahanKieran HorganPetra RauchhausRoberta LittlefordMarie CullbergElza C de BruinLoumpiana KoulaiJustin P O LindemannMartin PassPaul RugmanGaia SchiavonRahul DebPauline FinlayAndrew FoxleyJulia M W Gee

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Capivasertib 480 mg b.i.d. rapidly modulates key biomarkers of the AKT pathway and decreases proliferation marker Ki67, suggesting future potential as an effective therapy in AKT-dependent breast cancers.

Keyphrases

signaling pathway
cell proliferation
current status
stem cells
young adults
lymph node
human health
endoplasmic reticulum
mesenchymal stem cells
cell therapy